In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerat...
In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo
About this item
Full title
Publisher
New York: PR Newswire Association LLC
Journal title
Language
English
Formats
Publication information
Publisher
New York: PR Newswire Association LLC
Subjects
More information
Scope and Contents
Contents
CAMBRIDGE, Mass., May 21 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the results of a phase II trial of its investigational drug MLN02 in patients with ulcerative colitis, which showed statistically significant improvements in the clinical remission rates of patients treated with MLN02 compared to place...
Alternative Titles
Full title
In Phase II Study, Millennium Investigational Drug MLN02 Produced Significant Improvement in Ulcerative Colitis Remission Rates as Compared to Placebo
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_446963779
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_446963779
